Insider CFO Buys Moleculin Shares at Premium—A Signal of Confidence in Annamycin’s Potential
See how Moleculin Biotech CFO’s $0.75 share buy amid a 71% weekly drop signals confidence in its Annamycin pipeline and what that means for investors.
4 minutes to read
